Introduction
Ozempic (semaglutide) injection, for subcutaneous use, contains semaglutide, a human glp-1 receptor agonist (or glp-1 analog). The production of the peptide backbone via yeast fermentation.
Semaglutide’s primary method of protraction is albumin binding, which is made possible by modifying position 26 lysine with a hydrophilic spacer and a c18 fatty di-acid. Additionally, semaglutide undergoes a modification in position 8 to give stability against the enzyme dipeptidylpeptidase 4’s destruction (dpp-4). Position 34 was slightly altered to guarantee that only one fatty di-acid attached. The molecular weight per mole is 4113.58 g/mol, and the chemical formula is C187H291N45O59.
Ozempic is a sterile, aqueous, clear, colorless solution. each pre-filled pen contains a 1.5 ml solution of ozempic equivalent to 2 mg semaglutide. each 1 ml of ozempic solution contains 1.34 mg of semaglutide and the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14.0 mg; phenol, 5.50 mg; and water for injections. ozempic has a ph of approximately 7.4. hydrochloric acid or sodium hydroxide may be added to adjust ph.
Side Effects
The following serious adverse reactions are described below or elsewhere in the prescribing information:
Risk of Thyroid C-cell Tumors
Pancreatitis
Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Acute Kidney Injury
Hypersensitivitya
Reviews
There are no reviews yet.